© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Boxer Capital, LLC
Posted 26th February 2019

Boxer Capital, LLC

Boxer Capital, LLC invents and invests in biotechnology companies that aim to drastically improve medicine. To celebrate the firm’s success in this year’s Hedge Fund Awards we profile it to find out more and explore the secrets behind its success.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Boxer Capital, LLC

Boxer Capital, LLC

Boxer Capital, LLC invents and invests in biotechnology companies that aim to drastically improve medicine. To celebrate the firm’s success in this year’s Hedge Fund Awards we profile it to find out more and explore the secrets behind its success.

stablished in 2005 by Co-Founder, CEO, and Portfolio Manager, Aaron Davis; Co-Founder, Chris Fuglesang and its investor, Joe Lewis of the Tavistock Group, Boxer Capital leverages its internal expertise within the drug development and biotechnology industry to evaluate pre-clinical and clinical data from biotechnology companies that are positioned to generate outsized returns.

Boxer Capital maintains a portfolio of public and private companies, with a focus on biotechnology drug development across multiple therapeutic indications. Since its inception in 2005, the firm has achieved remarkable success, generating a 34% IRR and a cumulative return of 4,546%. In 2018, the firm generated an annual return of 70%, which, as notable as this is, still only serves as its fourth best annual return to date. Eight of the past 13 years, the firm has generated 30%+ returns.

Beyond its monetary growth, Boxer Capital has supported the advancement of therapeutic breakthroughs for oncology and rare disease patients through its wide-ranging investments in companies including:

• AveXis Inc. (AVXS): AVXS developed the proprietary gene therapy, AVXS-101, that changed disease progression of Spinal Muscular Atrophy (“SMA”) and ultimately led to the company’s acquisition by Novartis in April of 2018 for $8.7 billion USD

• BeiGene Ltd. (BGNE): BGNE takes an innovative approach in developing molecularly targeted and immune-oncology drugs to treat cancer

• Blueprint Medicines Corporation (BPMC): BPMC’s platform seeks to deliver a new generation of highly selective kinase therapies to dramatically improve patients’ lives

• Cougar Biotechnology (acquired by J&J in 2009): Cougar focused on treating metastatic castration-resistant prostate cancer through an inhibitor with antiandrogen activity. In May of 2009, Cougar was acquired by Johnson and Johnson for $1 billion USD

• Mirati Therapeutics (MRTX): MRTX is a clinical-stage oncology company developing targeted therapeutics to address the genetic, and immunological promoters of cancer.

Most of Boxer Capital’s investments begin from one of several proven investment theses, each involving substantial due diligence on fundamentals of the prospective company, paired with “big picture” thinking of the industry and sub-sectors. Through this disciplined methodology, the firm’s research and investment team identify opportunities to translate the inefficiencies of the biotechnology market into risk-adjusted returns over the short, medium, and long-term. 

Alongside their concentrated long portfolio exists an overall hedge of selective company and index shorts to balance their sector exposure in the markets. This investment approach has enabled Boxer Capital to remain a key player within the biotechnology investment space, giving it the ability to invest in research that will lead to some of the greatest developments in the medical markets in 2019 and beyond. 

Partnering with the brightest minds in science and medicine, Boxer Capital aims to help bring what was once only imaginable to reality. Every member of the Boxer Capital team takes pride in being at the forefront of improving outcomes for patients. Focusing most of their investment efforts on innovative discoveries that hold potential to bring life-saving options to patients, the firm has an underlying passion and expertise for investing in oncology. 

One of the current key challenges that exist within the biotechnology investment market is the continued drug pricing rhetoric and overhang from the political environment on desiring pricing change within the industry. Boxer Capital works to overcome these macro challenges of investing in the sector with a concentrated portfolio of long positions, focused mostly on companies developing drugs that will exponentially improve the current standard of care for patients; these must be “game changing” with a strong likelihood of success. Therefore, any major political or pricing shifts within the industry that may take form remain secondary in importance to the necessity for medical advancements to improve the daily lives of patients suffering from these illnesses. 

The firm’s key investor, Tavistock Group, is an international private investment organization founded by Joe Lewis over 40 years ago. Tavistock Group is built on a core philosophy to strive for excellence in everything it undertakes. Entrepreneurial and progressing, Tavistock Group values long-term relationships and identifies investment opportunities around the world that can benefit from capital, experience, flexibility, and a broad base of resources.

Boxer Capital’s international infrastructure and scale, coupled with its deep experience in biotechnology drug development and investing, positions them as one the premier life science investment firms in the industry. The firm’s expert team includes scientists and clinicians who have been on the forefront of research and discovery across multiple therapeutic indications; such as cardiovascular health, oncology, and neurological disease, among others. Several of the firm’s partners continue to practice medicine and have had the privilege of leading clinical development for multiple drugs that are treating patients today. This unique combination of medical and investing expertise has led to a 13-year proven track record.

Seeking to expand its marked success, Boxer Capital is working towards many exciting developments in the coming year. With strong returns since inception, Boxer Capital has expanded its team, adding several new members to its research department to help drive growth in 2019 and beyond, ensuring a bright future for both itself and Tavistock Group.

 

Company: Boxer Capital, LLC
Contact: Aaron Davis
Website: www.boxercap.com 

Categories: Finance, Innovation


You Might Also Like
Read Full PostRead - Eye Icon
CIO of the Month
Innovation
02/02/2016CIO of the Month

ZenithOptimedia is a leading global media services network with over 7,500 people working in 262 offices across 74 countries.

Read Full PostRead - Eye Icon
Money Grows: Increasing Your Capital
News
13/03/2023Money Grows: Increasing Your Capital

It can be reassuring to know that you are able to pay the bills and still have some cash left over at the end of the month. However, for many people, the last few days before payday can result in loans or credit cards being relied upon.

Read Full PostRead - Eye Icon
Save Time and Money with Clinical Maestro
Finance
27/04/2023Save Time and Money with Clinical Maestro

Strategikon has developed a platform called Clinical Maestro that is able to efficiently budget, source, and manage complex clinical programs.

Read Full PostRead - Eye Icon
Reasons Why IT Support Is More Critical Than Ever For Today’s Businesses
News
31/10/2022Reasons Why IT Support Is More Critical Than Ever For Today’s Businesses

As digital transformation and remote work continue to gain steam, IT services remain absolutely indispensable for businesses of all types and sizes. Whether an in-house team dedicated to the maintenance and upkeep of systems or a reliable outsourced support pr

Read Full PostRead - Eye Icon
Classic Car Insurance: Reasons You Need to Protect Your Investment
Legal
04/05/2023Classic Car Insurance: Reasons You Need to Protect Your Investment

Classic cars are a mark of elegance and durability, making them a valuable addition to your collection of vehicles. Due to their unique features, they will often require special care to last them through the years, allowing you to eliminate wear and tear that

Read Full PostRead - Eye Icon
Weld North LLC Completes Merger of Performance Matters and Truenorthlogic
Innovation
Read Full PostRead - Eye Icon
Tax Becomes the Talk of the Town
Finance
28/05/2015Tax Becomes the Talk of the Town

Survey for 10th Annual Domestic Tax Conference C-suite, boards, investors, media and legislators all interested in tax.

Read Full PostRead - Eye Icon
6 Reasons To Register Your Business Trademark
Legal
01/12/20226 Reasons To Register Your Business Trademark

When entrepreneurs start their businesses, they don't always consider trademarking them. However, having one has several benefits for your business. Your trade name is a valuable asset that might make you a fortune. A trademark is also an excellent way to prot

Read Full PostRead - Eye Icon
Structural Differences Between Futures and Spread Contracts
Finance
26/10/2026Structural Differences Between Futures and Spread Contracts

Futures and spread bets give traders access to many of the same markets, from equity indices and currencies to commodities and government bonds. On a price chart, the two can look almost interchangeable. Underneath that chart, however, they are built very diff



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow